These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30545995)

  • 1. Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer.
    Schuurhuizen CSEW; Marino P; Braamse AMJ; Buffart LM; Joly F; Fizazi K; Habibian M; Boher JM; Soulie M; Oudard S; Konings IRHM; Verheul HMW; Dekker J; Gravis G
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1481-1488. PubMed ID: 30545995
    [No Abstract]   [Full Text] [Related]  

  • 2. The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy.
    Schuurhuizen CS; Verheul HM; Braamse AM; Buffart LM; Bloemendal HJ; Dekker J; Konings IR
    Cancer Manag Res; 2018; 10():3015-3021. PubMed ID: 30214296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
    Marino P; Sfumato P; Joly F; Fizazi K; Oudard S; Culine S; Habibian M; Boher JM; Gravis G
    Eur J Cancer; 2017 Oct; 84():27-33. PubMed ID: 28780479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy.
    Lequesne J; Joly F; Peron J; Ray-Coquard I; Hardy-Bessard AC; Selle F; Berton D; Follana P; Fabbro M; Lortholary A; Pujade-Lauraine E; Lefèvre-Arbogast S; Coquan E
    J Natl Compr Canc Netw; 2023 May; 21(5):473-479.e4. PubMed ID: 37156482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    Morgans AK; Chen YH; Sweeney CJ; Jarrard DF; Plimack ER; Gartrell BA; Carducci MA; Hussain M; Garcia JA; Cella D; DiPaola RS; Patrick-Miller LJ
    J Clin Oncol; 2018 Apr; 36(11):1088-1095. PubMed ID: 29522362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
    Ooki A; Morita S; Iwamoto S; Hara H; Tanioka H; Satake H; Kataoka M; Kotaka M; Kagawa Y; Nakamura M; Shingai T; Ishikawa M; Miyake Y; Suto T; Hashiguchi Y; Yabuno T; Sakamoto J; Tsuji A; Ando M; Yamaguchi K
    Cancer Med; 2020 Mar; 9(5):1779-1789. PubMed ID: 31962002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
    Moinpour CM; Savage MJ; Troxel A; Lovato LC; Eisenberger M; Veith RW; Higgins B; Skeel R; Yee M; Blumenstein BA; Crawford ED; Meyskens FL
    J Natl Cancer Inst; 1998 Oct; 90(20):1537-44. PubMed ID: 9790546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
    Gravis G; Marino P; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Fizazi K
    Eur J Cancer; 2014 Mar; 50(5):953-62. PubMed ID: 24424105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).
    Al-Batran SE; Hozaeel W; Tauchert FK; Hofheinz RD; Hinke A; Windemuth-Kieselbach C; Hübner A; Burmester M; Koenigsmann M; Wiegand J; Zur Hausen G; Linsse B; Kuhl R; Pauligk C
    Ann Oncol; 2015 Jun; 26(6):1244-1248. PubMed ID: 25755108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial.
    Fernando HC; Landreneau RJ; Mandrekar SJ; Nichols FC; DiPetrillo TA; Meyers BF; Heron DE; Hillman SL; Jones DR; Starnes SL; Tan AD; Daly BD; Putnam JB;
    J Thorac Cardiovasc Surg; 2015 Mar; 149(3):718-25; discussion 725-6. PubMed ID: 25500100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
    Ferreira AR; Di Meglio A; Pistilli B; Gbenou AS; El-Mouhebb M; Dauchy S; Charles C; Joly F; Everhard S; Lambertini M; Coutant C; Cottu P; Lerebours F; Petit T; Dalenc F; Rouanet P; Arnaud A; Martin A; Berille J; Ganz PA; Partridge AH; Delaloge S; Michiels S; Andre F; Vaz-Luis I
    Ann Oncol; 2019 Nov; 30(11):1784-1795. PubMed ID: 31591636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer.
    Kyrdalen AE; Dahl AA; Hernes E; Småstuen MC; Fosså SD
    BJU Int; 2013 Feb; 111(2):221-32. PubMed ID: 22672151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
    Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.